CoChat

Addiction potential of phentermine prescribed during long-term treatment of obesity

Open access
Hendricks, E J, Srisurapanont, M, Schmidt, S L, Haggard, M, Souter, S, Mitchell, C L, De Marco, D G, Hendricks, M J, Istratiy, Y, Greenway, F L · 2014 · International Journal of Obesity
Cited by 67

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

To investigate if phentermine treatment induces phentermine abuse, psychological dependence (addiction) or phentermine drug craving in overweight, obese and weight loss maintenance patients. To investigate whether amphetamine-like withdrawal occurs after abrupt cessation of long-term phentermine treatment. Clinical intervention trial with interruption of phentermine treatment in long-term patients. 269 obese, overweight or formerly obese subjects (age: 20–88 years, BMI: 21–74 kg m−2) treated with phentermine long-term (LTP, N=117), 1.1–21.1 years, or short-term (ATP, N=152), 4–22 days, with phentermine doses of 18.75–112.5 (LTP) and 15–93.75 (ATP) mg per day. Module K of the Mini International Neuropsychiatric Interview modified for phentermine (MINI-SUD), Severity of Dependence Scale (SDS), 45-item Cocaine Craving Questionnaire-NOW (CCQ-NOW) modified for phentermine (PCQ-NOW), and Amphetamine Withdrawal Questionnaire (AWQ) modified for phentermine (PWQ). MINI-SUD interviews were negative for phentermine abuse or psychological dependence in all LTP patients. SDS examination scores were low for all LTP and ATP patients, indicating they were not psychologically dependent upon phentermine. PCQ-NOW scores were low for all LTP and ATP patients, indicating neither short-term nor long-term phentermine treatment had induced phentermine craving. Other than an increase in hunger or eating, amphetamine-like withdrawal symptoms did not occur upon abrupt phentermine cessation as measured by sequential PWQ scores. Phentermine abuse or psychological dependence (addiction) does not occur in patients treated with phentermine for obesity. Phentermine treatment does not induce phentermine drug craving, a hallmark sign of addiction. Amphetamine-like withdrawal does not occur upon abrupt treatment cessation even at doses much higher than commonly recommended and after treatment durations of up to 21 years. Phentermine was approved by the US FDA in 1959 for short term use for obesity. It is the most commonly used anti-obesity drug on the US market and many US bariatric physicians use phentermine long term, ignoring the FDA guidelines that it be used for three months or less. Phentermine is not approved for use in Europe and some other countries around the world because of the fear of addiction, tachycardia, and elevated blood pressure. Actual objective assessments of phentermine, as compared to administrative opinions, have been rare. The article by Hendricks et al in this issue is one of the few available in the literature. The study is not optimally designed, but suggests that fears of addiction to phentermine are exaggerated. None of the 269 subjects who had been on phentermine for up to 21 years demonstrated any addictive behavior as assessed by questionnaire and physical examination. Prior studies in the literature in monkeys did not demonstrate significant addictive potential. However, phentermine has a reputation as a “street drug” and is sold in Europe for high prices. Since the combination of phentermine and topiramate has just been approved for long term use in the US, government sponsored, well controlled research into the long term use of generic phentermine is needed. There is no possibility that any private company will do long term research on this generic drug. Should the fears regarding phentermine be shown to be groundless, the positions of governments to ban phentermine should be reconsidered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ijo.2013.74

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 67

Metadata

Authors
Hendricks, E. J., Srisurapanont, M., Schmidt, S. L., Haggard, M., Souter, S., Mitchell, C. L., De Marco, D. G., Hendricks, M. J., Istratiy, Y., & Greenway, F. L.
Venue
International Journal of Obesity
Published
2013-05-17
Volume
38
Issue
2
Pages
292-298
ISSN
  • 0307-0565 (ISSN-L)
  • 1476-5497
OpenAlex
W2071538269
Cited by
67
References
10
FWCI
4.13
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.